In the United States high-grade non-Hodgkins
lymphomas generally refer to three histological subtypes of
lymphoma categorized in the Working Formulation for Clinical Usage,
published over 16 years ago. The classification into low-,
intermediate- or high-grade lymphomas was mainly based on differences
in survival, and the three histological subtypes with the worst
prognosis were defined as high-grade (immunoblastic lymphoma,
lymphoblastic lymphoma, and small-noncleaved-cell lymphoma, which
were associated with 5-year survival rates of 32%, 26%, and 23%,
respectively). Small-noncleaved-cell lymphoma was further classified
into Burkitts and non-Burkitts lymphomas.
The decision to label immunoblastic lymphoma, lymphoblastic lymphoma,
and small-noncleaved-cell lymphoma as high-grade has been criticized
on a number of grounds.
First, the term grade is usually used in the context of
specific histopathological criteria rather than clinical outcome.
Second, in the study that led to the Working Formulation for Clinical
Usage, there was little or no attempt to take into consideration
either the treatment used (although most patients received an
anthracycline-containing regimen), or the prognostic factors that we
know to be critically important to the outcome of therapy. Even in
1982, better results than those recorded in the study that led to the
Working Formulation for Clinical Usage had been reported, at least in
children, for small-noncleaved-cell and lymphoblastic lymphoma [2-6],
so that the present, paradoxical situation in which the survival
rates of these high-grade lymphomas are much better than the survival
rates of either low-grade or intermediate-grade lymphomas were, even
then, beginning to become apparent.
Third, although differences in survival among the three grades
defined in the study that led to the Working Formulation for Clinical
Usage were statistically significant, there was clear overlap in the
survival rates of lymphomas classified as high and intermediate
grades, overlap that was not always reflected accurately by the
survival rates at 5 years. Clearly, the decisions as to where to draw
the line between high-grade and intermediate-grade was somewhat
arbitrary, as indeed, is the histological distinction between
small-noncleaved-cell lymphoma of non-Burkitts type and
large-cell lymphoma. Chromosomal translocations 8;14(q24;q32)
(which might be considered defining characteristics of Burkitts
lymphoma), are also observed in subsets of Burkitt-like lymphoma and
large-B-cell lymphoma, particularly in children.
Identifying High-Grade Lymphomas
The problem of the definition of a high-grade lymphoma has been
compounded by the identification, with the help of
immunohistochemical and molecular analyses, of new entities, some of
which (or some histological variants of which) would be classified as
high-grade in the Working Formulation for Clinical Usage. And,
finally, immunoblastic lymphoma cannot be reproducibly separated from
large-B-cell lymphoma, and there is disagreement among pathologists
as to whether it constitutes a separate entity.
The identification of prognostic groups has been greatly refined
since the early 1980s, particularly by the detailed analysis leading
to the International Prognostic Index, and such
prognostic factors work for all histologies. However, there is an
increasing recognition that each entity that can be precisely defined
behaves differently, and that the tendency to lump tumors together
for treatment purposes may not be wise. Certainly there is no a priori
reason to suppose that different biological entities will respond
similarly to the same therapythe reverse is often the case,
particularly in children. Unfortunately, while histology remains the
dominant means of making diagnoses, distinctions between biological
entities within a histological category will remain difficult at
best, and the hypothesis that genetically different tumors require
different therapies for optimal results will remain untested. Thus,
the use of broad risk groups that encompass multiple entities as a
continuing basis for the determination of therapy is of increasingly
There can be little doubt that the biological nature of the tumor
cell, in addition to the molecular genetic lesions that have modified
normal cellular behavior during the process of lymphomagenesis, are
the primary determinants of treatment outcome, although research is
urgently needed to determine whether molecular genetic markers
(particularly those that influence proliferation and apoptosis)
provide a more effective basis for treatment decisions than histology
(other factors, such as tumor burden and effective drug
concentrations will, doubtless, remain of significance, too).
Moreover, as novel therapies are introduced, (eg, monoclonal antibody
therapy such as anti-CD20 (rituximab [Rituxan]), or therapies
targeted towards specific molecular lesions or viral proteins present
in the tumor cells), the identification of the presence of specific
therapeutic targets is likely to become at least as important as
histology as a basis for therapeutic decisions.
With these considerations in mind, this article will deal with the
management of the three tumors, 1) Burkitts lymphoma, 2) the
B-cell tumors from the Working Formulation for Clinical Usages
category of non-Burkitts lymphoma (renamed in the more recent
Revised European American Lymphoma (REAL) classification 
Burkitt-like lymphoma), and 3) lymphoblastic lymphoma.
These tumors were defined on exclusively histological grounds in the
Working Formulation for Clinical Usage, but are specified as B-cell
neoplasms (in the case of Burkitts lymphoma and Burkitt-like
lymphoma), or neoplasms of precursor T or B cells in the case of
lymphoblastic lymphoma, in the REAL classification.
It is important to recognize that Burkitt-like lymphoma overlaps
considerably with both Burkitts lymphoma and large-B-cell
lymphoma and indeed, the dividing lines between these three
entities cannot be reproducibly made. It seems probable
that Burkitt-like lymphoma is not truly a separate diesease, but is
composed of a mixture of Burkitts lymphoma and large-B-cell
lymphoma, the relative proportion of large-B-cell lymphoma increasing
with age. However, Burkitt-like lymphoma appears, in general, to have
a clinical behavior pattern and response to therapy similar to
Burkitts lymphoma (and will be included with Burkitt's lymphoma
for the purposes of this article) such that its large-B-cell lymphoma
element is likely to consist predominantly of a subtype of
large-B-cell lymphoma. For therapeutic purposes it may remain
appropriate to separate this category from large-B-cell lymphoma in
some way. However, in children, large-B-cell lymphoma has a similar
prognosis to Burkitts lymphoma and Burkitt-like lymphoma when
treated with the same chemotherapy regimens.[2-4] Whether this would
apply to the large-B-cell lymphomas of adults is not known. All three
of the neoplasms dealt with in this article have a peak incidence in
the first 2 decades of life and are the predominant non-Hodgkins
lymphomas of childhood and adolescence, but account for only a few
percent of cases of adult non-Hodgkins lymphoma.
1. National Cancer Institute-sponsored study of the classifications
of non-Hodgkins lymphomas: Summary and description of a working
formulation for clinical usage. Cancer 49: 2112-2135, 1982.
2. Adde M, Shad A, Venzon D et al: Additional chemotherapy agents
improve treatment outcome for children and adults with advanced
B-cell lymphomas. Semin Oncol 2(Suppl 4):33-39, 1998.
3. Reiter A, Schrappe M, Parwaresch R, et al: Non-Hodgkins
lymphomas of childhood and adolescence: Results of a treatment
stratified for biologic subtypes and stagea report of the Berlin-Frankfurt-Munster
Group. J Clin Oncol 2:359-372, 1995
4. Patte C, Michon J, Frappaz D, et al: Therapy of Burkitt and other
B-cell acute lymphoblastic leukaemia and lymphoma: Experience with
the LMB protocols of the SFOP(French Paediatric Oncology Society) in
children and adults. Baillieres Clin Haematol 2:339-248, 1994.
5. Brecher ML, Schwenn MR, Coppes MJ, et al: Fractionated
cylophosphamide and back to back high dose methotrexate and cytosine
arabinoside improves outcome in patients with stage III high grade
small non-cleaved cell lymphomas (SNCCL): A randomized trial of the
Pediatric Oncology Group.Med Pediatr Oncol 6:526-533, 1997.
6. Magrath IT: The treatment of pediatric lymphomas: paradigms to
plagiarize? Ann Oncol 8(Suppl 1):7-14, 1997.
7. Magrath IT: Introduction: Concepts and controversies in lymphoid
neoplasia. In The Non-Hodgkins Lymphomas, second edition. Ed,
Ian Magrath. Arnold, London, pp 3-46, 1997.
8. Siebert R, Matthiesen P, Harder S, et al: Application of
interphase fluorescence in situ Hybridization for the detection of
the Burkitt translocation t(8;14)(q24;q32) in B-cell lymphomas. Blood
9. Engelhard M, Brittinger G, Huhn D, et al: Subclassification of
diffuse large B-cell lymphomas according to the Kiel classification:
Distinction of centroblastic and immunoblastic lymphomas is a
significant prognostic risk factor. Blood 89:2291-2297, 1997.
10. Harris NL, Jaffe ES, Stein H, et al: A revised European-American
classification of lymphoid neoplasms: a proposal from the
International Lymphoma Study Group. Blood 84:1361-1392, 1994.
11. Miller TP, Grogan TM, Dahlberg S, et al: Prognostic significance
of the Ki-67-associated proliferativeantigen in aggressive
non-Hodgkins lymphomas: a prospective Southwest Oncology Group
trial. Blood 83:1460-1466, 1994.
12. Rivera-Luna R, Martinez-Guerra G, Martinez-Avalos A, et al:
Treatment of non-Hodgkins lymphoma in Mexican children. The
effectiveness of chemotherapy during malnutrition. Am J Pediatr
Hematol Oncol 9:356-366, 1987.
13. Link MP, Donaldson SS, Berard CW, et al: Results of treatment of
childhood localized non-Hodgkins Iymphoma with combination
chemotherapy with or without radiotherapy. N Engl J Med
14. Wong ET, Portlock CS, OBrien JP, et al: Chemosensitive
epidural spinal cord disease in non-Hodgkins lymphoma. Neurology
15. Miron I, Frappaz D, Brunat-Mentigny M, et al: Initial management
of advanced Burkitt lymphoma in children: is there still a place for
surgery? Pediatr Hematol Oncol 14:555-561, 1997.
16. Anderson JR, Jenkin RD, Wilson JF, et al: Long-term follow-up of
patients treated with COMP or LSA2L2 therapy for childhood
non-Hodgkins lymphoma: A report of CCG-551 from the Childrens
Cancer Group. J Clin Oncol 11:1024-1032, 1993.
17. Link MP, Shuster JJ, Donaldson SS, et al: Treatment of children
and young adults with early-stage non-Hodgkins lymphoma. N Engl
J Med 337:1259-1266, 1997.
18. Magrath I, Adde M, Sandlund J, et al: Ifosfamide in the treatment
of high-grade recurrent non-Hodgkins lymphomas. Hematol Oncol
19. Gentet JC, Patte C, Quintana E: Phase II study of cytarabine and
etoposide in children with refractory or relapsed non-Hodgkins
lymphoma: A study of the French Society of Pediatric. Oncology.J Clin
Oncol 8(4):661-665, 1995.
20. Patte C, Bernard A, Hartmann O, et al: High-dose methotrexate and
continuous infusion Ara-C in childrens non-Hodgkins
lymphoma: phase II studies and their use in further protocols.
Pediatr Hematol Oncol 3:11-18, 1986.
21. Magrath I, Adde M, Shad A, et al: Adults and children with small
non-cleaved-cell lymphoma have a similar excellent outcome when
treated with the same chemotherapy regimen. J Clin Oncol 14:925-934, 1996.
22. Burkitt D: Long-term remissions following one and two dose
chemotherapy for African lymphoma. Cancer 20:756-59, 1967.
23. Link MP, Shuster JJ, Hutchison RE, et al: Minimizing therapy for
children with localized non-Hodgkins lymphomas of hte
gastrointestinal tract. Proc Am Soc Clin Oncol 17:528a (A2030), 1998.
24. Reiter A, Schrappe M, Ludwig WD, et al: Favorable outcome of
B-cell acute lymphoblastic leukemia in childhood: a report of three
consecutive studies of the BFM group. Blood 80:2471-2478, 1992.
25. Bowman WP, Shuster JJ, Cook B, et al: Improved survival for
children with B-cell acute lymphoblastic leukemia and stage IV small
noncleaved-cell lymphoma: A pediatric oncology group study. J Clin
Oncol 14:1252-1261, 1996.
26. Waits TM, Greco FA, Greer JP, et al: Treatment of poor prognosis
non-Hodgkins lymphoma with intensive, inpatient combination
chemotherapy of brief duration: long-term follow-up. Leuk Lymphoma
27. Lepage E, Gisselbrecht C, Haioun C, et al: Prognostic
significance of received relative dose intensity in non-Hodgkins
lymphoma patients: application to LNH-87 protocol. The GELA (Groupe
dEtude des Lymphomes de lAdulte). Ann Oncol 4:6510-656, 1993.
28. Lopez TM, Hagemeister FB, McLoughlin P, et al: Small noncleaved
cell lymphoma in adults: Superior results for stages I-III disease. J
Clin Oncol 8:615-622, 1990.
29. McMaster ML, Greer JP, Greco FA, et al: Effective treatment of
small noncleaved cell lymphoma with high-intensity, brief duration
chemotherapy. J Clin Oncol 9:941-946, 1991.
30. Mazza JJ, Hines JD, Andersen JW, et al: Aggressive chemotherapy
in the treatment of Burkitts and non-Burkitts
undifferentiated lymphoma. Leukemia and Lymphoma 18: 289-96, 1995.
31. Soussain C, Patte C, Ostronoff M, et al: Small noncleaved cell
lymphoma and leukemia in adults. A retrospective study of 65 adults
treated with the LMB pediatric protocols. Blood 85:664-674, 1995.
32. Pees HW, Radtke H, Schwamborn J, et al: The BFM-protocol for
HIV-negative Burkitts lymphomas and L3 acute lymphoblastic
leukemia in adult patients: a high chance for cure. Ann Hematol
33. Todeschini G, Tecchio C, Degani D, et al: Eighty-one percent
event-free survival in advanced Burkitts lymphoma/leukemia: No
differences in outcome between pediatric and adult patients treated
with the same intensive pediatric protocol. Ann Oncol 8(Suppl
34. Tubergen DG, Krailo MD, Meadows AT, et al: Comparison of
treatment regimens for pediatric lymphoblastic non-Hodgkins
lymphoma: A Childrens Cancer Group study. J Clin Oncol 13:1368-1376,
35. Patte C, Kalifa C, Flamant F, et al: Results of the LMT81
Protocol, a modified LSA2L2 protocol with high dose methotrexate, on
84 children with non-B-cell (lymphoblastic) lymphoma. Med Pediatr
Oncol 20:105-113, 1992.
36. Schrappe M, Tiemann M, Ludwig WD, et al: Risk-adapted therapy for
lymphoblastic T-cell lymphoma: Results from trials NHL-BFM 86 and 90.
Med and Ped Oncol 29:356(A-0-141), 1997.
37. Vose JM, Armitage JO: The present status of therapy for patients
with aggressive non-Hodgkins lymphoma. Ann Oncol 2(Suppl
38. Colgan JP, Andersen J, Habermann TM, et al: Long-term follow-up
of a CHOP-based regimen with maintenance therapy and central nervous
system prophylaxis in lymphoblastic non-Hodgkins lymphoma. Leuk
Lymphoma 15:291-296, 1994.
39. Coleman CN, Picozzi VJ Jr, Cox RS, et al: Treatment of
lymphoblastic lymphoma in adults. J Clin Oncol 11:1628-1637, 1986.
40. Slater DE, Mertelsmann R, Koziner B, et al: Lymphoblastic
lymphoma in adults. J Clin Oncol 1:57-67, 1986.
41. Bernasconi C, Brusamolino E, Lazzarino M, et al: Lymphoblastic
lymphoma in adult patients: Clinicopathological features and response
to intensive multiagent chemotherapy analogous to that used in acute
lymphoblastic leukemia. Ann Oncol 1:141-146, 1990.
42. Morel P, Lepage E, Brice P, et al: Prognosis and treatment of
lymphoblastic lymphoma in adults: A report on 80 patients. J Clin
Oncol 7:1078-1085, 1992.
43. Cherlow JM, Steinherz PG, Sather HN, et al: The role of radiation
therapy in the treatment of acute lymphoblastic leukemia with
lymphomatous presentation: A report from the Childrens Cancer Group.
Int J Radiat Oncol Biol Phys 27:1001-1009, 1993.
44. Sweetenham JW, Pearce R, Taghipour G, et al: Adult Burkitts
and Burkitt-like non-Hodgkins lymphoma-outcome for patients
treated with high-dose therapy and autologous stem-cell
transplantation in first remission or at relapse: results from the
European Group for Blood and Marrow Transplantation. J Clin Oncol
45. Pettengell R, Radford JA, Morgenstern GR, et al: Survival benefit
from high-dose therapy with autologous blood progenitor-cell
transplantation in poor-prognosis non-Hodgkins lymphoma. J Clin
Oncol 14:586-592, 1996.
46. Bouabdallah R, Xerri L , Bardou V-J, et al: Role of induction
chemotherapy and bone marrow transplantation in adult lymphoblastic
lymphoma: a report on 62 patients from a single center. Ann Oncol
47. Sweetenham JW, Liberti G, Pearce R, et al: High-dose therapy and
autologous bone marrow transplantation of adult patients with
lymphobastic lymphoma: Results of the European Group for Bone Marrow
Transplantation. J Clin Oncol 12:1358-1365, 1994.
48. Santini G, Congiu AM, Coser P, et al: Autologous bone marrow
transplantation for adult advanced stage lymphoblastic lymphoma in
first CR. A study of the NHLSCG. Leukemia 5(Suppl 1):42-45, 1991.
49. Ladenstein R, Pearce R, Hartmann O, et al: High-dose chemotherapy
with autologous bone marrow rescue in children with poor-risk
Burkitts lymphoma: A report from the European Lymphoma Bone
Marrow Transplantation Registry. Blood 90:2921-2930, 1997.
50. Khanna R, Cooper L, Kienzle N, et al: Engagement of CD40 antigen
with soluble CD40 ligand up-regulates peptide transporter expression
and restores endogenous processing function in Burkitts
lymphoma cells. J Immunol 159:5782-5785, 1997.
51. Judde JG, Spangler G, Magrath I, et al: Use of Epstein-Barr virus
nuclear antigen-1 in targeted therapy of EBV-associated neoplasia.
Hum Gene Ther 7:647-653, 1996.
52. Gutierrez MI, Judde JG, Magrath IT, et al: Switching viral
latency to viral lysis: A novel therapeutic approach for Epstein-Barr
virus-associated neoplasia. Cancer Res 56:969-972, 1996.
53. Smith JB, Wickstrom E: Antisense c-myc and immunostimulatory
oligonucleotide inhibition of tumorigenesis in a murine B-cell
lymphoma transplant model. J Natl Cancer Inst 90:1146-1154, 1998.
54. French RR, Penney CA, Browning AC: Delivery of the
ribosome-inactivating protein, gelonin, to lymphoma cells via CD22
and CD38 using bispecific antibodies. Br J Cancer 71:986-994, 1995.
55. Sang BC, Shi L, Dias P, et al: Monoclonal antibodies specific to
the acute lymphoblastic leukemia t(1;19)-associated E2A/pbx1 chimeric
protein: Characterization and diagnostic utility. Blood 89:2909-2914, 1997.